Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial

- BMI above or equal to 30 kg/m^2

- Male or female, age 18 years or older at the time of signing informed consent

Exclusion Criteria:

- HbA1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), or
diagnosis of type 1 or type 2 diabetes mellitus

- Recent history of cardiovascular disease (myocardial infarction or stroke within the
past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree
or greater heart block

- Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine
Neoplasia type 2 (MEN2)

- Female who is pregnant, breast-feeding or intends to become pregnant or is of
child-bearing potential and not using an adequate contraceptive method (adequate
contraceptive measure as required by local regulation or practice)

- Use in past 90 days of medications known to induce significant weight loss (e.g.,
prescription weight loss medications) or weight gain (e.g., chronic use of oral
steroids, second generation antipsychotics)

- History of pancreatitis (acute or chronic)

- History of major depressive disorder within the past 2 years

- Any lifetime history of a suicide attempt

- Inadequately treated blood pressure defined as Grade 3 hypertension or higher
(Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg)

- History of malignancy (except for non-melanoma skin cancer) within the past 5 years